Posts

Biopharma Bites: Boehringer’s 2Q, Keytruda Expansion, and Wegovy’s Market Domination

on

The Oral GLP-1 Tracker: Novo’s Wegovy keeps gaining ground in obesity market

on

Oral GLP‑1 Tracker: Novo’s oral Wegovy hits 3M prescription milestone as Lilly’s Foundayo chugs along in early launch

on

Lilly and Novo Face Off at ADA 2026 as Others Seek to Compete in Obesity

on

Lilly's Foundayo and Zepbound to gain CVS coverage, lifting sales outlook

on

Eli Lilly's Orforglipron Obesity Pill Gains FDA Approval, Challenging Novo Nordisk's Wegovy

on

FDA Approves Novo Nordisk's Awiqli: First Once-Weekly Basal Insulin for Type 2 Diabetes

on

Recent Biotech and Pharma News - March 2026

on

Novo Holdings Assets Shrink by a Third Due to Novo Nordisk's Falling Share Price

on

Hims Pharmacy Partner Plans to Reintroduce GLP-1 Pill Pulled from Market Amid Regulatory Backlash

on

Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front

on

Oral Wegovy Attracts Thousands of New GLP-1 Patients

on

Hims & Hers Abandons Plans for Compounded GLP-1 Pill Amid FDA and Novo Nordisk Backlash

on

Valo Health Appoints Karin Conde-Knape as Chief Scientific Officer

on

JPM26 Live Blog Day 2: GSK Stays the Course Amid Key Biopharma Updates

on

White House unveils nine new “most-favored-nation” drug pricing deals

on

Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama

on

Mikael Dolsten Withdraws Candidacy for Novo Nordisk Board; Bavarian Nordic Chairman Resigns

on

Korro Bio Abandons Lead Genetic Disease Drug Candidate KRRO-110 After Disappointing Trial Data

on

Pfizer Triumphs Over Novo Nordisk with $10B Bid to Acquire Metsera

on